Sustained remission of CIDP associated with Evans syndrome
- PMID: 15326255
- DOI: 10.1212/01.wnl.0000134606.50529.c7
Sustained remission of CIDP associated with Evans syndrome
Abstract
A patient with chronic inflammatory demyelinating polyneuropathy (CIDP) developed Evans syndrome (hemolytic anemia/thrombocytopenia) 17 months after onset of symptoms despite different immunomodulatory treatments. A therapeutic approach with the chimeric monoclonal anti-CD20 antibody rituximab induced substantial improvement of CIDP and hematologic recovery. The patient remains in sustained remission 17 months after completion of therapy. Rituximab may represent a successful therapy in otherwise refractory CIDP.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources